Not necessarily... to some extent it depends on how conclusive...

Not necessarily... to some extent it depends on how conclusive the data is from the 2A study. If the results are completely unambiguous and profound, with no indications of side-effects, then you can be pretty confident in the phase 2B, especially with a peptide drug.

Phase 3 is another matter, but peptide drugs passing Phase 2 have a good history in Phase 3.